House lawmakers late Wednesday evening (March 9) passed by a vote of 260--171 a bipartisan, bicameral omnibus spending bill that gives FDA $3.3 billion in discretionary funding for fiscal 2022, a $102 million increase over fiscal 2021 levels but still less than what House and Senate appropriators proposed for the agency last year during their first attempt at passing fiscal 2022 funding legislation. The funding provides resources for FDA to address the opioid crisis and rare cancers, enhance medical supply...